CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals

This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLE...

ver descrição completa

Detalhes bibliográficos
Autores: Campo, Marta del, Quesada, Carlos, Vermunt, Lisa, Peeters, Carel F. W., Hok-A-Hin, Yanaika S., Trieu, Calvin, den Braber, Anouk, Verberk, Inge M. W., Visser, Pieter Jelle, Tijms, Betty M., van der Flier, Wiesje M., Teunissen, Charlotte E.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/72200
Acesso em linha:https://hdl.handle.net/10230/72200
http://dx.doi.org/10.1186/s13024-024-00767-z
http://hdl.handle.net/10230/72200
Access Level:acceso abierto
Palavra-chave:Alzheimer, Malaltia d&apos
Descrição
Resumo:This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.

Registos relacionados